NCT06883539View on ClinicalTrials.gov

A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

June 30, 2028

Conditions
Solid Tumor Malignancies, CancerSolid CancersSolid Tumor CancerSolid Tumor, Unspecified, AdultSolid TumourSolid Tumors Refractory to Standard TherapyHCC - Hepatocellular CarcinomaRCC, Renal Cell CancerPancreas Cancer
Interventions
DRUG

LXP1788 is administered intravenously via Port-A

LXP1788 Injection is formulated as a solution for injection and will be administered intravenously for 60 minutes on days 1, 8, 15, 22 of the cycle. Each cycle will be 28 days.

Trial Locations (2)

404

RECRUITING

China Medical University Hospital, Taichung

704

RECRUITING

National Cheng Kung University Hospital, Tainan City

All Listed Sponsors
collaborator

Efficient Pharma Management Corp.

INDUSTRY

lead

LaunXP Biomedical Co., Ltd.

INDUSTRY